How big is ARS Pharmaceuticals, Inc.?

As of Jun 18, ARS Pharmaceuticals, Inc. has a market capitalization of 1,455.53 million, with net sales of 97.12 million and a net profit of -15.66 million over the last four quarters. Shareholder's funds are 256.80 million, and total assets are 351.15 million.

Market Cap: As of Jun 18, ARS Pharmaceuticals, Inc. has a market capitalization of 1,455.53 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 97.12 million and a net profit of -15.66 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 256.80 million, while total assets were reported at 351.15 million.

What does ARS Pharmaceuticals, Inc. do?

ARS Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $34 million as of March 2025. The company has a market cap of $1.46 billion and does not pay dividends.

Overview: <BR>ARS Pharmaceuticals, Inc. operates within the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,455.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.20 <BR>Return on Equity: -6.88% <BR>Price to Book: 6.36<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold ARS Pharmaceuticals, Inc.?

Is ARS Pharmaceuticals, Inc. overvalued or undervalued?

As of May 14, 2025, ARS Pharmaceuticals, Inc. is considered overvalued and risky due to negative earnings and high valuation ratios, including a price-to-book value of 6.22 and a P/E ratio of -92.41, despite outperforming the S&P 500 with a 102.82% return over the past year.

As of 14 May 2025, ARS Pharmaceuticals, Inc. has moved from an expensive to a risky valuation grade. The company is currently considered overvalued given its negative earnings and high valuation ratios. Key ratios include a price-to-book value of 6.22, an EV to EBITDA ratio of -43.15, and a return on equity (ROE) of -6.88%. <BR><BR>In comparison to peers, ARS Pharmaceuticals has a significantly lower P/E ratio of -92.41, while Procaps Group SA is rated very attractive with a P/E of 605.22, highlighting the disparity in valuation. Other risky peers like Liquidia Corp. show a P/E of -8.60, further indicating that ARS Pharmaceuticals is not competitively valued within its industry. Notably, the company's stock has outperformed the S&P 500 over the past year, returning 102.82% compared to the index's 10.26%, but this does not mitigate the concerns regarding its current valuation status.

Is ARS Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, ARS Pharmaceuticals, Inc. is in a bearish trend, indicated by negative technical indicators and underperformance with a year-to-date return of -2.65% compared to the S&P 500's 14.18%.

As of 3 October 2025, the technical trend for ARS Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly and mildly bearish on the monthly. There are no signals from the RSI, and Dow Theory shows no trend in both weekly and monthly perspectives. <BR><BR>In terms of performance, ARS Pharmaceuticals has underperformed the S&P 500 on a year-to-date basis, with a return of -2.65% compared to the S&P 500's 14.18%, and has significantly lagged over the past year with a return of -27.63% versus the S&P 500's 17.82%.